Skip to main content
SpringerLink
Log in

Antidepressive Monotherapie

  • Chapter
Akute und therapieresistente Depressionen

  • 4477 Accesses

Zusammenfassung

In diesem Beitrag wird die Wirksamkeit einer antidepressiven Monotherapie nach erfolgloser Vorbehandlung mit einem Antidepressivum aus einer anderen Klasse untersucht. Eine systematische Literaturrecherche ergab, dass es zu dieser Frage insgesamt sehr wenige Daten aus kontrollierten Studien gibt. Es fanden sich nur 5 randomisierte Studien, 6 Cross-over-Studien, 16 offene Studien und eine systematische Übersichtsarbeit. Der Wechsel von einem Antidepressivum zu einem anderen bei der therapieresistenten Depression ist bisher nicht nur wenig, sondern darüber hinaus auch nur unzureichend untersucht: Keine der Studien erfüllte alle CONSORT-Kriterien für die Darstellung randomisierter, kontrollierter Studien. Insgesamt handelt es sich um eine weit verbreitete klinische Praxis ohne ausreichende wissenschaftliche Fundierung. Daher besteht dringender Bedarf an pragmatischen, neuen randomisierten, kontrollierten Studien mit möglichst alltagsnahen Einschlusskriterien.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Aberg-Wistedt A (1982) A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. Acta Psychiatr Scand 66: 50–65

    PubMed  Google Scholar 

  • American Psychiatric Association (2000) Practice guidelines for the treatment of major depressive disorder (Revision). Am J Psychiatry 157 [Suppl Apr]: 1–43

    Google Scholar 

  • Begg C, Cho M, Eastwood S et al. (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276: 637–639

    Article  PubMed  Google Scholar 

  • Bonner D, Howard R (1995) Clinical characteristics of resistant depression in the elderly. Int J Geriatr Psychiatry 10: 1023–1027

    Article  Google Scholar 

  • Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ (2002) Identification of a claims data «signature» and economic consequences for treatment-resistant depression. J Clin Psychiatr 63: 717–726

    Google Scholar 

  • Dabkowska M, Rybakowski JK (1993) Moclobemide in treatment-resistant depression. Eur Neuropsychopharmacol 3: 328–329

    Article  Google Scholar 

  • Drago F, Motta A, Grossi E (1983) Intravenous maprotiline in severe and resistant primary depression: a double-blind comparison with clomipramine. J Int Med Res 11: 78–84

    PubMed  Google Scholar 

  • Dyck MJ (1994) Treatment resistant depression: a critique of current approaches. Aust NZ J Psychiatry 28: 34–41

    Google Scholar 

  • Emrich HM, Berger M, Riemann D, von Zerssen D (1987) Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry 20: 60–63

    PubMed  Google Scholar 

  • Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatric Clin North Am 19: 179–200

    Article  Google Scholar 

  • Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajekka J, Cohen M (2001) Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 62: 413–420

    PubMed  Google Scholar 

  • Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P (2003) Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry 15: 17–22

    PubMed  Google Scholar 

  • Ferguson J, Cunningham L, Merideth C et al. (1994) Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry 6: 153–159

    PubMed  Google Scholar 

  • Flint AJ, Rifat SL (1996) The effect of sequential antidepressant treatment on geriatric depression. J Aff Disord 36: 95–105

    Article  Google Scholar 

  • Greden JF (2001) The burden of disease for treatment resistant depression. J Clin Psychiatry 62[Suppl 16]: 26–31

    Google Scholar 

  • Hese RT, Gruszczynski W, Szwed A, Kielc M, Zalitac M (2002) The comparative studies of therapeutic results in patients with psychotic refractory depression treated with selected antidepressants and unilateral ECT. Psychiatria Polska 6[Suppl]: 81–84

    Google Scholar 

  • Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991) Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148: 910–916

    PubMed  Google Scholar 

  • Kaplan EM (2002) Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther 24: 1194–1200

    Article  PubMed  Google Scholar 

  • Kornstein SG, Schneider RK (2001) Clinical features of treatment resistant depression. J Clin Psychiatry 62[Suppl 16]: 18–25

    Google Scholar 

  • McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, Klein DF (1993) A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 150: 118–123

    PubMed  Google Scholar 

  • McIntyre RS, Muller A, Mancini DA, Silver ES (2003) What to do if an initial antidepressant fails? Can Fam Physician 49: 449–457

    PubMed  Google Scholar 

  • Michalak EE (2003) Commentary. Review: there is limited evidence about the effectiveness of interventions for treatment-refractory depression. Evidence-Based Mental Health 6: 48

    PubMed  Google Scholar 

  • Nelson JC (2003) Managing treatment-resistant major depression. J Clin Psychiatry 64[Suppl 1]: 5–12

    Google Scholar 

  • Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ 3rd, Rosenbaum JF, Fava M (1999) Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60: 221–225

    PubMed  Google Scholar 

  • Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M (2003) Nortriptiline for treatment-resistant depression. J Clin Psychiatry 64: 35–39

    Google Scholar 

  • Nolen WA, van de Putte JJ, WA Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J (1988a) Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 78: 668–675

    PubMed  Google Scholar 

  • Nolen WA, van de Putte JJ, WA Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J (1988b) Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 78: 676–683

    PubMed  Google Scholar 

  • Nolen WA, Haffmans PM, Bouvy PF, Duivenvoorden HJ (1993) Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 28: 189–197

    Article  PubMed  Google Scholar 

  • Papakostas GI, Petersen T, Pava J, Masson BA, Worthington JJ, Alpert JE, Fava M, Nierenberg AA (2003) Hopeless and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis 191: 444–449

    PubMed  Google Scholar 

  • Poirier MF, Boyer P (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 175: 12–16

    PubMed  Google Scholar 

  • Saiz-Ruiz J, Ibanez A, Diaz-Marsa M et al. (2002) Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 26: 1129–1134

    Article  PubMed  Google Scholar 

  • Sourey D, Amsterdam J, de Montigny C et al. (1999) Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacology 9: 83–91

    Article  Google Scholar 

  • Stimpson N, Agrawal N, Lewis G (2002) Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Br J Psychiatry 181: 284–294

    Article  PubMed  Google Scholar 

  • Tanghe A, Steeman J, Bollen E, van Renynghe de Voxvrie G, Dendooven M, Haazen L (1997) Moclobemide and amitriptyline, alone or in combination, in therapy resistant depression (Letter). Hum Psychopharmacol 12: 509–510

    Article  Google Scholar 

  • Thase ME (2001) The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatr 62: 221–224

    Google Scholar 

  • Thase ME, Mallinger AG, McKnight D, Himmelhoch JM (1992) Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 149: 195–198

    PubMed  Google Scholar 

  • Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG (1997) Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 58: 16–21

    Google Scholar 

  • Thase ME, Friedman ES, Howland RH (2000a) Venlafaxine and treatment-resistant depression. Depres Anx 12[Suppl 1]: 55–62

    Article  Google Scholar 

  • Thase ME, Friedman ES, Fasiczka AL, Berman SR, Frank E, Nofzinger EA, Reynolds 3rd CF (2000b) Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. J Clin Psychiatry 61: 466–472

    PubMed  Google Scholar 

  • Thase ME, Feighner JP, Lydiard RB (2001a) Citalopram treatment of fluoxetine non-responders. J Clin Psychiatry 62: 683–687

    PubMed  Google Scholar 

  • Thase ME, Kremer C, Rodrigues H (2001b) Mirtazapine vs. Sertraline after SSRI non-response. Results of a doubleblind switch study. Eur Neurpsychopharmacol 11[Suppl 3]: S342

    Article  Google Scholar 

  • Thase ME, Rush AJ, Howland RH et al. (2002) Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59: 233–239

    Article  PubMed  Google Scholar 

  • Trivedi MH (2003) Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry 15: 59–70

    PubMed  Google Scholar 

  • Volz HP, Faltus F, Magyar I, Moeller HJ (1994) Brofaromine in treatment-resistant depressed patients — a comparative trial versus tranylcypromine. J Aff Disord 30: 209–217

    Article  Google Scholar 

  • Weintraub D (2001) Nortriptiline in geriatric depression resistant to serotonin reuptake inhibitors: case series. J Geriatr Psychiatr Neurol 14: 28–32

    Google Scholar 

  • World Psychiatric Association (1974) Symposium on therapy resistant depression. Pharmacopsychotherapy 7: 69–224

    Google Scholar 

Download references

Authors
  1. A. Cipriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Barbui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Baethge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Wilder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Geddes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychatrie und Psychotherapie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Schumannstr. 20/21, 10117, Berlin

    Michael Bauer  & Mazda Adli  & 

  2. Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Luisenstr. 57, 10117, Berlin

    Anne Berghöfer

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Cipriani, A., Barbui, C., Baethge, C., Wilder, H., Geddes, J. (2005). Antidepressive Monotherapie. In: Bauer, M., Berghöfer, A., Adli, M. (eds) Akute und therapieresistente Depressionen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28049-9_14

Download citation

  • DOI: https://doi.org/10.1007/3-540-28049-9_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40617-4

  • Online ISBN: 978-3-540-28049-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation